PANCREATIC PHARMACEUTICALS AIM
Pancreatic Pharmaceuticals (spin off company of Micar Innovation) is specialized in the discovery, development and commercialization of the small molecule drugs and transforming the treatment of Pancreatic cancer by advancing one of the largest, exclusively cancer-focused clinical pipelines of novel therapies. By using structure based in silico drug design & AI (Micar21 platform) we constructed the best Pancreatic Cancer drug candidate fast & validated.
We aim to bridge the safety and efficacy gaps in current approaches to Pancreatic Cancer management. Pancreatic Pharmaceuticals lead drug candidate, MIC6479, is currently in the phase preclinical for the treatment of Pancreatic Cancer.
Type of organization: Company
Address: 38A, Karamfil street, 1616, Sofia, Bulgaria
Dimitar Dimitrov, Interim CEO & Co-Founder
Organzation: Pancreatic Pharmaceuticals